rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GTCB 2007 ******

2.783 Posts
Pagina: «« 1 ... 40 41 42 43 44 ... 140 »» | Laatste | Omlaag ↓
  1. [verwijderd] 7 maart 2007 07:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. In August 2006,ATryn®, GTC’s recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. This was the first approval anywhere in the world of a therapeutic protein produced from a transgenic animal.ATryn®is in phase III studies to support a filing in the United States requesting approval in the hereditary deficiency indication. In addition, GTC has established a strategic collaboration with LFB Biotechnologies of France to jointly develop recombinant forms of human plasma proteins and monoclonal antibodies. The first program of the collaboration will be to develop recombinant human factor VIIa as a potential treatment for hemophilia in patients with antibodies to other coagulation factors.



    GTC has also recently been granted a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC’s transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, www.gtc-bio.com.

    BIO Dree
  2. [verwijderd] 8 maart 2007 12:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    February-20-2007


    Charles de Vaulx Buys Lockheed Martin Corp., WellPoint Inc., Express Scripts Inc., Sells Waste Management Inc., Northwestern Corp., Orthologic Corp.

    Ticker Date* Price* buy/sell Picked By
    MDT 2006-12-31 $50.8 Buy Bill Nygren
    HD 2006-12-31 $37.8 Add Richard Pzena
    APA 2006-12-31 $66.2 Add Charles de Vaulx
    MDT 2006-12-31 $50.8 Add Charles de Vaulx
    MHS 2006-12-31 $52.5 Add Charles de Vaulx

    *The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available.
    Value investor Charles de Vaulx minimizes his investment risk by focusing on securities that are considered to be undervalued by the market. This is the updates of his buys and sells during the 4th quarter of 2006. Charles de Vaulx owns 388 stocks with a total value of $13.4 billion as of 12/31/2006.

    Charles de Vaulx buys Lockheed Martin Corp., WellPoint Inc., Express Scripts Inc., Linear Technology Corp., Meredith Corp., Caremark Rx Inc., Mercantile Bankshares Corp., ISHARES LEHMAN 20 YR, Maxim Integrated Products Inc., Texas Instruments Inc., Columbia Equity Trust Inc., Equity Office Properties Trust, Duke Energy Corp., HEALTHSOUTH CP, Clark Inc., St. Jude Medical Inc., Abbott Laboratories, TECK COMINCO CL B, Eagle Materials Inc., Digitas Inc., DYNCORP INTL INC., Halliburton Co., Barclays plc, Agere Systems Inc., MDS Inc., Government Properties Trust In, AirTran Holdings Inc., Apollo Group Inc., 3M Co., TD Banknorth Inc., FUJIFILM HOLDINGS CORPORATION - AMERICAN DEPOSITAR, Penn West Energy Trust, Suntech Power Holdings Co., Ltd. American Deposita, CombinatoRx, Incorporated - Common, Buffalo Wild Wings Inc., AMER ITAL PASTA, Nuvelo Inc., The Hanover Insurance Group, Inc. , MGP Ingredients Inc., Microtek Medical Holdings Inc., Sky Financial Group Inc., Sirius Satellite Radio Inc., SGX PHARMACEUTICALS, INC., Sanmina-SCI Corp., Skyworks Solutions Inc., Napster Inc., Embarq Corporation , Telstra Corp. Ltd., NATCO Group Inc., , Tejon Ranch Co., Ultra Petroleum Corp., Veeco Instruments Inc., MEMC Electronic Materials Inc., Midwest Air Group Inc., Patterson-UTI Energy Inc., IntercontinentalExchange, Inc. , par v, DB Commodity Index Tracking Fund, ENTERRA EN TR, America First Apartment Invest, Essex Property Trust Inc., EWZ, Gemstar-TV Guide International, Lithia Motors Inc., Genitope Corp., Computer Programs & Systems In, Onyx Pharmaceuticals Inc., Japan Smaller Capitalization Fund, Inc. Common Sto, International Securities Excha, Dionex Corp., InfoSpace Inc., Harvest Energy Trust Trust Units, Annaly Mortgage Management Inc, ReGen Biologics Inc., Columbia Equity Trust Inc., sells Waste Management Inc., Northwestern Corp., Orthologic Corp., Mittal Steel Company NV, Panera Bread Co., , Interpublic Group of Companies, Five Star Quality Care Inc., Fisher Communications Inc., First Data Corp., Elephant Talk Communications I, NitroMed Inc., Retail HOLDRS, Witness Systems Inc., Windstream Corporation , Wendy's International Inc., Unitedhealth Group Inc., Titan Pharmaceuticals Inc., Toll Brothers Inc., SPY, Staples Inc., Sherwin-Williams Co., Sepracor Inc., EOG Resources Inc., Dell Inc., Coinstar Inc., American Power Conversion Corp, Alteon Inc., Advanced Life Sciences Holding, Asbury Automotive Group Inc., Live Nation, Inc. , Maverick Oil and Gas Inc., MTR Gaming Group Inc., The9 Ltd., MasterCard Incorporated Class A , Molex Inc., ARADIGM CORP, Arena Pharmaceuticals Inc., Applera Corp-Celera Genomics G, Corcept Therapeutics Inc., China Netcom Group Corp. (Hong, China Unicom Ltd., Cephalon Inc., Canyon Resources Corp., Peabody Energy Corp., Bolt Technology Corp., Birch Mountain Resources Ltd., Bally Total Fitness Holding Co, MDC Holdings Inc. during the 3-months ended 12/31/2006, according to the most recent filings of his investment company, Arnhold & S. Bleichroeder Advisers, LLC. Charles de Vaulx owns 388 stocks with a total value of $13.4 billion. These are the details of the buys and sells.



    New Purchases: AAI, ABT, AGR, APOL, APRO, BCS, BNK, BWLD, CLK, CMX, COE, CPSI, CRXX, DBC, DCP, DNEX, DUK, ENT, EQ, ESRX, ESS, EWZ, EXP, FUJI, GMST, GPT, GTOP, HAL, HLS, HTE, ICE, INSP, ISE, JOF, LAD, LLTC, LMT, MDP, MDZ, MEH, MGPI, MMM, MRBK, MTMD, MXIM, NAPS, NLY, NTG, NUVO, ONXX, PTEN, PWE, SANM, SGXP, SIRI, SKYF, STJ, STP, SWKS, TCK, THG, TLS, TLT, TPTX, TRC, TXN, UPL, VECO, WFR, WLP, RGBI.OB, COE,
    Added Positions: ABY, ADI, APA, ASD, AT, AU, AVAN, BAX, BEZ, BNP, BSG, CCO, CTAS, CY, CYCC, CYTC, DEL, DLIA, EMMS, GE, GG, GLD, GNLB, GTCB, H, HAE, HD, HIG, ICLR, IDIX, IDXX, KEYS, KMX, KOSN, LEXG, LQU, LTM, MANH, MDT, MGRM, MHS, MO, MRX, NLC, NPSP, NRG, NYT, OIH, ORLY, PPDI, PRAI, RESP, SENEA, SWK, TMO, TRB, TRX, ZBRA, GNLB, SENEA, DEL, APH, NLC, WEYS,
    Reduced Positions: ABX, AMRI, ANSV, ARRY, ATX, AXP, BIIB, BMY, CAKE, DKS, EPL, GBE, GD, GPS, HANS, HON, HRS, IDA, IWOV, JNS, MEDI, MEDX, NG, NKE, PDE, PTN, SGP, SNUS, TEK, TM, TSCO, TWX, UST, UTX, UVN, VIA-B, WB, WY, CAU,
    Sold Out: ABG, ADLS, ALT, ARNA, BFT, BMD, BTJ, BTU, CAU, CEPH, CHU, CN, CORT, CRA, CSTR, DELL, EOG, ETLK.OB, FDC, FSCI, FVE, IPG, IWD, LYV, MA, MDC, MNTG, MOLX, MT, MVOG.OB, NCTY, NTMD, NWEC, OLGC, PNRA, RTH, SEPR, SHW, SPLS, SPY, TOL, TTP, UNH, WEN, WIN, WITS, WMI
  3. [verwijderd] 8 maart 2007 12:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Rh Lactoferrin werkzaam tegen kanker in hoofdhalsgebied
    « on: 08-03-2007 09:33:21 »

    --------------------------------------------------------------------------------
    Clin Cancer Res. 2007 Mar 1;13(5):1601-10.

    Oral Lactoferrin Results in T Cell-Dependent Tumor Inhibition of Head and Neck Squamous Cell Carcinoma In vivo.

    Wolf JS, Li G, Varadhachary A, Petrak K, Schneyer M, Li D, Ongkasuwan J, Zhang X, Taylor RJ, Strome SE, O'malley BW Jr.

    Authors' Affiliations: 1 Department of Otorhinolaryngology-Head and Neck Surgery and 2 Program in Oncology, Stewart and Marlene Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland; 3 Agennix, Inc., Houston, Texas; and 4 Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

    PURPOSE: Human lactoferrin is a naturally occurring glycoprotein that inhibits cancer growth. Our purpose was to evaluate recombinant human lactoferrin as a chemotherapeutic agent against head and neck squamous cell carcinoma. EXPERIMENTAL DESIGN: Controlled experiments both in vitro and in the murine model evaluating both the effect and mechanism of lactoferrin on cancer growth. RESULTS: In both human and murine cell lines, lactoferrin induced dose-dependent growth inhibition. Using flow cytometric analysis, lactoferrin was shown to induce G(1)-G(0) growth arrest. This arrest seemed to be modulated by down-regulation of cyclin D1. In the in vitro model, luminex data revealed that lactoferrin inhibited cellular release of proinflammatory and prometastatic cytokines, including interleukin-8, interleukin-6, granulocyte macrophage colony-stimulating factor, and tumor necrosis factor-alpha. Lactoferrin up-regulated the cellular activation of nuclear factor-kappaB within 4 h of cellular exposure. In C3h/HeJ mice implanted with SCCVII tumors, orally delivered lactoferrin inhibited tumor growth by 75% compared with control mice. Immunohistochemical analysis of harvested tumors revealed up to 20-fold increases of lymphocytes within treated animals. When mice were depleted of CD3(+) cells, all lactoferrin-induced tumor inhibition was abrogated. CONCLUSION: We conclude that human recombinant lactoferrin can inhibit the growth of head and neck squamous cell carcinoma via direct cellular inhibition as well as systemically via immunomodulation. Our data support the study of human lactoferrin as an immunomodulatory compound with therapeutic potential.

    PMID: 17332307 [PubMed
    BIO Dree
  14. [verwijderd] 9 maart 2007 11:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ja weet niet of ik nu nog moeten handelen. Denk dat ik maar wat rustiger aan ga doen of even zoeken op google of er toch iets anders is.
    Dastrader vraagt 125$ per maand! grrr
2.783 Posts
Pagina: «« 1 ... 40 41 42 43 44 ... 140 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.018
AB InBev 2 5.501
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.684
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.703
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.856
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.339
Air France - KLM 1.025 35.047
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.862
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.251
AMG 971 133.372
AMS 3 73
Amsterdam Commodities 305 6.690
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.008
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.780
Arcelor Mittal 2.033 320.717
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.741
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.154
ASML 1.766 107.476
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.674
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392